English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

A radioreceptor assay (RRA) for the quantitative determination of a new antiallergic agent, 1- (2-ethoxyethyl) -2- (4-methyl-1-homopiperazinyl) benzimidazole difumarate (KB-2413), has been developed. This RRA method, based upon competitive binding of [3H] mepyramine and KB-2413 to histamine H1 receptors in guinea pig cerebellum, allows the simple, sensitive and reproducible determination of KB-2413 in plasma. The determination limit was 0.1 ng (as free base) /ml and the standard curve was linear over the range of 0.1 to 5.0 ng/ml. The intra-and inter-assay coefficients of variation for the determination of KB-2413 were 5.2-11.1 % and 3.4-5.6%, respectively. The active metabolites, 1- (2-ethoxyethyl) -2- (1-homopiperazinyl) benzimidazole and 1- (2-ethoxyethyl) -5-hydroxy-2- (4-methyl-1-homopiperazinyl) benzimidazole, cross-reacted to the extents of 28.6 and 21.1 %, respectively. However, plasma levels obtained by the RRA method and the gas chromatographic method for the intact drug were well correlated in guinea pigs after oral administration of KB-2413.

Radioreceptor assay for a new antiallergic agent, 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)benzimidazole difumarate (KB-2413), in plasma.